Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnevist-enhanced MRA in calf and pedal artery disease
NCT00309075Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2003
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of gadopentetate dimeglumine in peripheral artery disease (PAD), sponsored by Bayer. Started Dec 2003; status: completed.
02
Drugs
gadopentetate dimeglumine
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT00309075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309075.